NovoCure Financial Statements
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NovoCure revenue and earnings
In fiscal 2025, NovoCure generated $655.4 million in revenue, up 8.3% from fiscal 2024, its 2nd consecutive year of revenue growth. NovoCure reported a net loss of $136.2 million, compared with a loss of $168.6 million a year earlier. Gross margin was 74.5% (down from 77.3%) and operating margin -23.5%.
Diluted earnings per share came in at -$1.22. Over the last 5 fiscal years, NVCR's revenue has grown at a 5.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
NovoCure income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 655.35M | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M | 351.32M | 248.07M | 177.03M | 82.89M |
| Revenue growth (YoY) | +8.28% | +18.82% | -5.30% | +0.53% | +8.23% | +40.72% | +41.62% | +40.13% | +113.57% | +150.52% |
| Cost of Revenue | 166.88M | 137.18M | 128.28M | 114.87M | 114.88M | 106.50M | 88.61M | 80.05M | 55.61M | 39.87M |
| Gross Profit | 488.47M | 468.04M | 381.06M | 422.97M | 420.15M | 387.87M | 262.71M | 168.02M | 121.42M | 36.61M |
| Operating Expenses | 642.27M | 638.53M | 613.93M | 512.50M | 464.49M | 357.46M | 263.63M | 201.69M | 160.75M | 151.92M |
| Research & Development | 224.54M | 209.65M | 223.06M | 206.09M | 201.30M | 132.01M | 79.00M | 50.57M | 38.10M | 41.47M |
| Selling, General & Admin | 417.73M | 428.89M | 390.87M | 306.41M | 263.18M | 225.45M | 184.62M | 151.12M | 122.64M | 110.46M |
| Operating Income | -153.80M | -170.50M | -232.87M | -89.52M | -44.33M | 30.40M | -914.00K | -33.67M | -39.33M | -115.32M |
| Interest Expense | 22.22M | 11.66M | 4.91M | 8.11M | 8.84M | 18.05M | 14.64M | 16.91M | 11.69M | 7.32M |
| Pretax Income | -136.25M | -131.16M | -191.74M | -81.85M | -52.08M | 18.10M | -8.82M | -45.94M | -48.50M | -121.46M |
| Income Tax | -23.00K | 37.47M | 15.30M | 10.69M | 6.28M | -1.71M | -1.59M | 17.62M | 13.16M | 10.38M |
| Net Income | -136.23M | -168.63M | -207.04M | -92.53M | -58.35M | 19.81M | -7.23M | -63.56M | -61.66M | -131.84M |
| Net Income growth (YoY) | — | — | — | — | -394.58% | — | — | — | — | — |
| EPS (Basic) | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | -0.70 | -1.54 |
| EPS (Diluted) | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 | -0.69 | -0.70 | -1.54 |
| Shares Outstanding (Basic) | 111.47M | 107.83M | 106.39M | 104.66M | 103.43M | 100.93M | 97.24M | 91.83M | 88.55M | 85.56M |
| Shares Outstanding (Diluted) | 111.47M | 107.83M | 106.39M | 104.66M | 103.43M | 108.88M | 97.24M | 91.83M | 88.55M | 85.56M |
| EBITDA | -139.15M | -159.26M | -221.90M | -78.90M | -34.08M | 39.55M | 7.55M | -24.67M | -31.65M | -109.67M |
| Gross Margin | 74.54% | 77.33% | 74.81% | 78.64% | 78.53% | 78.46% | 74.78% | 67.73% | 68.59% | 44.16% |
| Operating Margin | -23.47% | -28.17% | -45.72% | -16.64% | -8.29% | 6.15% | -26.00% | -13.57% | -22.22% | -139.12% |
| Net Margin | -20.79% | -27.86% | -40.65% | -17.20% | -10.91% | 4.01% | -2.06% | -25.62% | -34.83% | -159.06% |
This table shows 10 annual periods of NovoCure's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NVCR's reporting calendar. What is a income statement?